Lost in Float with #FloatForMAPS
A Float Therapy Industry-Wide Gift Card Campaign Launching July 2018 to Support PTSD Research
Float For Maps Gift Card Campaign
We are excited to announce that for the entire month of July, we are launching a gift card campaign to raise funds for groundbreaking post-traumatic stress disorder (PTSD) research being conducted by Multidisciplinary Association for Psychedelic Studies (MAPS).
The 1st week of July
#FloatForMAPS Gift Cards are
Buy 1 Float for $65 Get 1 Float FREE!
For EVERY #FloatForMAPS gift card purchased, we will donate 15% of the proceeds directly to MAPS in order to continue research and get this treatment to the people in need.
WHAT IS #FLOATFORMAPS?
Created by Michael Garrett of Reboot and Ryan Duey of Capitol Floats, #FloatForMAPS is a float industry-wide gift card campaign taking place July 2018 that will generate funds for both the Multidisciplinary Association for Psychedelic Studies (MAPS / maps.org). Participating centers, including Lost in Float, will donate 15% of their #FloatForMaps Gift Cards to MAPS in support of their drug development of MDMA-assisted psychotherapy for PTSD.
Float Centers Participating Globally
Funds raised for MAPS.org
People made aware of MAPS’s PTSD research
WHAT IS MAPS?
Founded in 1986 by Rick Doblin, Ph.D., the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Their most recent study is using MDMA-assisted psychotherapy for the treatment of severe post traumatic stress disorder. To learn more, visit the MAPS website: maps.org
RESULTS FROM PHASE II TRIALS
In MAPS’ completed Phase 2 trials with 107 participants, 56% no longer qualified for PTSD after treatment, measured two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. These participants all had chronic, treatment-resistant PTSD, and most only received two or three sessions of MDMA-assisted psychotherapy, along with twelve 90-minute psychotherapy sessions for preparation and integration.
No longer had PTSD
MAPS had breakthrough results on their Phase 2 trials of MDMA-assisted psychotherapy for PTSD, and are now conducting Phase 3 trials, the final stage of research before the U.S. Food and Drug Administration (FDA) can approve a new prescription treatment. MAPS currently aims to submit its New Drug Application to the FDA in 2021 for approval. Drug development is expensive, but with our help, MAPS will be able to make this PTSD treatment widely available to the 25 million people in the world who are suffering from serious trauma.